Ceftazidime/avibactam serum concentration in patients on ECMO.

Anaïs CurtiaudMatthieu PetitJuliette ChommelouxMarc Pineton de ChambrunGuillaume HekimianMatthieu SchmidtAlain CombesCharles-Edouard Luyt

Published in: The Journal of antimicrobial chemotherapy (2024)

In ECMO patients receiving ceftazidime/avibactam, ceftazidime and avibactam serum levels are above EUCAST breakpoints in most cases, justifying the use of normal dosing in ECMO patients. Increased renal clearance may lead to ceftazidime and avibactam under dosing.

Keyphrases

gram negative
end stage renal disease
extracorporeal membrane oxygenation
ejection fraction
newly diagnosed
acute respiratory distress syndrome
chronic kidney disease
klebsiella pneumoniae
prognostic factors
multidrug resistant
peritoneal dialysis
escherichia coli
respiratory failure
patient reported outcomes